stockrow
Saturday 7 November 2026
Export GRDX’s income statement to Excel — free account
GridAI Technologies Corp.
GRDX Healthcare Biotechnology
GridAI Technologies Corp.’s revenue for fiscal 2025 (year ended December 2025) was $36,300.00.
- EPS
- −773.9%
- Free cash flow
- −2,641.0%
- Total debt
- −64.0%
Quarter to June 2026, against a year earlier
4.79
0.12
+2.57%
Follow GRDX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 0 | — | — | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | (1,811.02) | 0.00 | (1,811.0) pt | ||||||
| EBT | (15) | (11) | (14) | (15) | (33) | (59) | (15) | (16) | (16) | (7) | (22) | (8.4%) | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (18,292.01) | 0.00 | (18,292.0) pt | ||||||
| Net income | (15) | (11) | (14) | (15) | (33) | (59) | (15) | (16) | (18) | (7) | (21) | (8.5%) | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | n/m | |||||
| Earnings | (2.24) | (1.04) | (0.88) | (0.68) | (184,914.00) | (119,415.70) | (1,260.13) | (143.65) | (15.99) | (4.16) | (5.45) | +7.1% | ||||||
| Cash flow | (0.70) | (0.68) | (0.70) | (0.63) | (49,723.06) | (46,126.00) | (1,862.01) | (110.42) | (8.05) | (3.53) | (1.27) | +19.7% | ||||||
| Capex | 0.00 | 0.00 | (0.02) | 0.00 | 387.27 | (99.29) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (0.70) | (0.68) | (0.72) | (0.63) | (49,335.79) | (46,225.29) | (1,862.01) | (110.42) | (8.05) | (3.53) | (1.27) | +19.7% | ||||||
| Book value | 0.49 | 0.16 | 0.29 | 0.21 | (11,701.08) | (11,173.71) | 228.52 | 32.14 | 50.48 | 17.83 | 2.92 | +49.0% | ||||||
| Shares, m | 7 | 11 | 15 | 22 | 0 | 0 | 0 | 0 | 1 | 2 | 4 | (14.3%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | 0.30 | 2.07 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (2.34) | (4.45) | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (5) | (7) | (11) | (14) | (11) | (32) | (22) | (12) | (9) | (6) | (8) | +2.6% | |||||
| Capex | 0 | 0 | 0 | 0 | 0 | 0 | — | — | — | — | 0 | +41.2% | ||||||
| Free cash flow | (5) | (7) | (11) | (14) | (11) | (32) | (22) | (12) | (9) | (6) | (8) | +2.5% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 1 | (1) | 2 | (1) | (8) | (3) | 1 | 2 | 56 | (13) | (12) | n/m | |||||
| Net debt | (2) | 0 | (1) | 1 | (5) | (8) | (1) | (4) | 23 | (1) | (1) | (9.9%) | ||||||
| Shareholders’ equity | 3 | 2 | 4 | 5 | (3) | (8) | 3 | 4 | 58 | 29 | 19 | +27.6% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (217.15) | (181.41) | (209.03) | (185.41) | (382.40) | (683.98) | (173.81) | (261.35) | (39.66) | (10.05) | (34.14) | +207.1 pt | |||||
| ROIC | (247.90) | (475.14) | (232.25) | (166.99) | 0.00 | 0.00 | (386.73) | 0.00 | (12.12) | (15.70) | (79.29) | +232.2 pt | ||||||
| ROE | 749.10 | (455.37) | (441.23) | (333.90) | (4,222.85) | 1,615.68 | 589.55 | (507.58) | 13,367.64 | (63.89) | (485.88) | (813.0) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 8 | 13 | 12 | 10 | 12 | 17 | 10 | 9 | 2 | 2 | — | (14.3%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
GridAI Technologies Corp. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| TVGN Tevogen Inc. | $36.2M | — (loss-making) | — | — | n/m | +5.78% (above 0%: growing) | — | 0.00% | Compare |
| PTHS Pelthos Therapeutics Inc. | $35.6M | — (loss-making) | — (loss-making) | — | n/m | −1,614.99% (below 0%: shrinking) | 76.86% | (111.02%) | Compare |
| VERU Veru Inc. | $35.1M | — (loss-making) | — (loss-making) | +99.23% (above 0%: growing) | n/m | +0.27% (above 0%: growing) | 67.84% | 0.00% | Compare |
| LIANY LianBio Sponsored ADR | $34.2M | 0.0× | — | — | n/m | +1,107.59% (above 0%: growing) | 0.00% | 0.00% | Compare |
| GRDX GridAI Technologies Corp. | $33.3M | — (loss-making) | — | — | n/m | −2,640.98% (below 0%: shrinking) | (42.49%) | (15,258.21%) | |
| NNVC NanoViricides, Inc. | $32.9M | — (loss-making) | — | — | n/m | −23.94% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PMN Promis Neurosciences | $32.7M | — (loss-making) | — | 0.00% | n/m | −169.46% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| INMB INmune Bio, Inc. | $32.6M | — (loss-making) | — (loss-making) | +8.70% (above 0%: growing) | n/m | +55.39% (above 0%: growing) | 100.00% | 0.00% | Compare |
| EYPT EyePoint, Inc. | $30.7M | — (loss-making) | — (loss-making) | −90.49% (below 0%: shrinking) | n/m | +0.41% (above 0%: growing) | 100.00% | (19,207.10%) | Compare |
| Median of peers | $33.6M | — | — | +4.35% | — | +0.34% | 67.84% | 0.00% |
Pay and ownership Proxy statement filed 4 June 2025
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2024 | 510.31k | 510.31k | (0.10) |
| 2023 | 1.25m | 671.31k | (28.20) |
| 2022 | 741.72k | 184.27k | (48.49) |
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Read the proxy statement